Japanese company developing drug to grow new teeth, plans for clinical trials on humans in 2024
By Brianna Morris-Grant
54 minutes ago
The company has already tested the drug on ferrets. (Photo: Kyodo News)
A drug to grow new teeth is being developed at a Japanese pharmaceutical company, with hopes to begin clinical trials in less than a year.
Toregem Biopharma, funded by Kyoto University, has developed an antibody drug which inhibits the protein in the mouth that suppresses growth and stops "tooth buds" from developing.
The team has already successfully administered the drug to ferrets, which have both baby and permanent teeth similar to humans, in 2018.
They want to see trials on humans in July 2024, and want the drug on the market by 2030. The company also plans for a second clinical trial on children born without some or all of their teeth.
Toregem's president Honoka Kiso wrote on the company's website she had lost teeth due to a bone disease when she was a teenager.
"I wanted to study the cause of my illness and how to regenerate lost teeth," she said.
"Toregem Biopharma first hope to treat patients with congenital tooth loss who do not grow permanent tooth buds due to genetic causes.
"[Our] final goal is to offer advanced and scientifically driven clinical solution for the growth of teeth derived from their own tissues."
Toregem has said "inactivating the USAG-1 protein" allows teeth to grow.
Company co-founder and head of dentistry and oral surgery at Osaka's Kitano Hospital, Masaru Takahashi, said missing teeth in children affected the development of the jawbone.
'We would like to address these concerns with dental medicine," he said.
By Brianna Morris-Grant
54 minutes ago
The company has already tested the drug on ferrets. (Photo: Kyodo News)
A drug to grow new teeth is being developed at a Japanese pharmaceutical company, with hopes to begin clinical trials in less than a year.
Toregem Biopharma, funded by Kyoto University, has developed an antibody drug which inhibits the protein in the mouth that suppresses growth and stops "tooth buds" from developing.
The team has already successfully administered the drug to ferrets, which have both baby and permanent teeth similar to humans, in 2018.
They want to see trials on humans in July 2024, and want the drug on the market by 2030. The company also plans for a second clinical trial on children born without some or all of their teeth.
Toregem's president Honoka Kiso wrote on the company's website she had lost teeth due to a bone disease when she was a teenager.
"I wanted to study the cause of my illness and how to regenerate lost teeth," she said.
"Toregem Biopharma first hope to treat patients with congenital tooth loss who do not grow permanent tooth buds due to genetic causes.
"[Our] final goal is to offer advanced and scientifically driven clinical solution for the growth of teeth derived from their own tissues."
Toregem has said "inactivating the USAG-1 protein" allows teeth to grow.
Company co-founder and head of dentistry and oral surgery at Osaka's Kitano Hospital, Masaru Takahashi, said missing teeth in children affected the development of the jawbone.
'We would like to address these concerns with dental medicine," he said.
Similar Readings (5 items)
Japan's health ministry to decide whether to approve new Alzheimer's drug
Tokyo hospital starts administering new Alzheimer's drug
Japan health ministry panel approves new Alzheimer's drug
Eisai applies for approval of new Alzheimer's drug in Japan
Japan health ministry panel endorses Alzheimer's drug donanemab
Summary
Japanese pharmaceutical company Toregem Biopharma, funded by Kyoto University, is developing an antibody drug to inhibit the protein that suppresses tooth growth. Clinical trials on humans are planned for July 2024, with a focus on treating patients with congenital tooth loss. The team aims to